197299-16-4

Usage

Uses

Used in Fragrance Industry:
ETHYL 2-ETHOXY-3-(4-HYDROXYPHENYL)PROPIONATE is used as a fragrance ingredient for its sweet, floral scent, contributing to the aroma profiles of perfumes, soaps, and other personal care products.
Used in Flavor Industry:
In the flavor industry, ETHYL 2-ETHOXY-3-(4-HYDROXYPHENYL)PROPIONATE is used as a flavoring agent, particularly in food products such as confectionery and beverages, enhancing their taste and appeal.
Used in Cosmetic Products:
ETHYL 2-ETHOXY-3-(4-HYDROXYPHENYL)PROPIONATE is used as an antioxidant in cosmetic products to protect the skin from oxidative damage, thereby contributing to the maintenance of skin health and appearance.
Used in Antioxidant Formulations:
Its antioxidant properties also make ETHYL 2-ETHOXY-3-(4-HYDROXYPHENYL)PROPIONATE a component in formulations designed to counteract oxidative stress, which is beneficial in various applications across different industries.

InChI:InChI=1/C13H18O4/c1-3-16-12(13(15)17-4-2)9-10-5-7-11(14)8-6-10/h5-8,12,14H,3-4,9H2,1-2H3

Upstream product

• 4397-53-9 p-benzyloxybenzaldehyde 
• 13676-06-7 ethyl 2-ethoxy-2-(diethylphosphono)acetate 
• 34006-60-5 ethyl 2-chloro-2-ethoxyacetate 
• 6065-82-3 Ethyl diethoxyacetate 
• 123-08-0 4-hydroxy-benzaldehyde 
• 141109-83-3 ethyl 3-(4-benzyloxyphenyl)lactate 
• 62517-34-4 ethyl 2-hydroxy-3-(4-hydroxyphenyl)propionate 
• 817-95-8 ethyl 2-ethoxyethanoate 
• 223126-28-1 3-(4-benzyloxyphenyl)-2-ethoxypropanoic acid ethyl ester 
• 222835-03-2 3-(4-benzyloxy-phenyl)-2-ethoxy-acrylic acid ethyl ester 

Downstream Products

• 265130-72-1 ethyl 2-ethoxy-3-(4-[2-(9H-xanthen-9-yl)ethoxy]phenyl)propionate 
• 265130-58-3 ethyl 2-ethoxy-3-[4-(2-fluoren-9-ylidene-ethoxy)-phenyl]-propionate 
• 265130-62-9 ethyl 2-ethoxy-3-[4-(2-(9H-fluoren-9-yl)ethoxy]phenyl)propionate 
• 877615-48-0 3-{4-[2-(4'-bromo-biphenyl-4-yloxy)-ethoxy]-phenyl}-2-ethoxy-propionic acid ethyl ester 
• 719293-66-0 3-(4-dimethylthiocarbamoyloxy-phenyl)-2-ethoxy-propionic acid ethyl ester 
• 352286-22-7 (E)-(S)-3-{4-[3-(4'-bromo-biphenyl-4-yl)-but-2-enyloxy]-phenyl}-2-ethoxy-propionic acid ethyl ester 
• 222554-24-7 (+/-)-Ethyl 2-ethoxy-3-[4-[2-[4-oxo-3,4-dihydro-1,3-benzoxazin-3-yl]ethoxy]phenyl]propanoate 
• 220746-98-5 ethyl 2-ethoxy-3-[4-(2-bromoethoxy)-phenyl]propanoate 
• 900865-00-1 Ethyl 3-{4-[2-(6-benzoyl-4,4-dimethyl-1,2,3,4-tetrahydro-1-quinolinyl)ethoxy]phenyl}-2-ethoxypropanoate 
• 222555-05-7 ethyl (2R)-2-ethoxy-3-(4-hydroxyphenyl)propanoate 
• 325793-65-5 (2S)-2-Ethoxy-3-(4-hydroxyphenyl)propanoic acid 
• 1056456-28-0 (S)-2-ethoxy-3-(4-((3-methylthiophen-2-yl)methoxy)phenyl)propionic acid ethyl ester 
• 1056456-04-2 (S)-3-(4-((5-bromo-3-methylthiophen-2-yl)methoxy)phenyl)-2-ethoxypropionic acid ethyl ester 
• 1056455-43-6 (S)-2-ethoxy-3-(4-((5-(3-methoxyphenyl)-3-methylthiophen-2-yl)methoxy)phenyl)propionic acid 

Relevant academic research and scientific papers

Process development on the enantioselective enzymatic hydrolysis of S-ethyl 2-ethoxy-3-(4-hydroxyphenyl)propanoate

A novel biocatalytic approach for the large-scale production of S-2-ethoxy-3-(4-hydroxyphenyl)propanoic acid S-1 from its racemic ethylester rac-2 by enantioselective hydrolysis has been developed. S-1 is an important building block in the synthesis of PPARα and -γ agonists such as Ragaglitazar [NNC 61-0029 ((-)DRF2725)]. The development history comprises enzyme screening, biocatalyst and process optimization, and scale-up to pilot plant. The project was thereby highly interdisciplinary by combining biotechnology and chemistry technologies. The final process was successfully run on a 44-kg pilot scale in 43-48% yields and with high enantiomeric purities (98.4-99.6% ee).

PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compou

NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS

The present invention disclosed compounds of Structural Formula (I), and enantiomer, racemic body, pharmaceutically acceptable salts, solvates or hydrates thereof, wherein variable groups are as defined within, as well as methods for preparing such compou

4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARα/γ agonists. Part I: Synthesis and pharmacological evaluation

Type-2 diabetes (T2D) is a complex metabolic disease characterized by insulin resistance in the liver and peripheral tissues accompanied by a defect in pancreatic β-cell. Since their discovery three subtypes of Peroxisomes Proliferators Activated Receptors were identified namely PPARα, PPARγ and PPARβ/(δ). We were interested in designing novel PPARγ selective agonists and/or dual PPARα/γ agonists. Based on the typical topology of synthetic PPAR agonists, we focused our design approach on 4,4-dimethyl-1,2,3,4-tetrahydroquinoline as novel cyclic tail.

NOVEL PHENYLPROPIONIC ACID DERIVATIVES AS PEROXISOME PROLIFERATOR-ACTIVATED GAMMA RECEPTOR MODULATORS, METHOD OF THE SAME, AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME

The present invention provides a novel phenylpropionic acid derivative and a PPAR-γ modulator comprising the same as an active ingredient. The phenylpropionic acid derivative of the present invention has modulatory action on function of PPAR-γ and then exhibits hypoglycemic, hypolipidemic and insulin resistance-reducing effects on PPAR-mediated diseases or disorders. Therefore, the present invention is prophylactically or therapeutically effective for diabetes and metabolic diseases.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

COMPOUNDS AND COMPOSITIONS AS PPAR MODULATORS

The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of the Peroxisome Proliferator-Activated Receptor (PPAR) families.

Design, synthesis, and structure-activity relationship of carbamate-tethered aryl propanoic acids as novel PPARα/γ dual agonists

We have developed a new class of PPARα/γ dual agonists, which show excellent agonistic activity in PPARα/γ transactivation assay. In particular, (R)-9d was identified as a potent PPARα/γ dual agonist with EC50s of 0.377 μM in PPARα and 0.136 μM in PPARγ, respectively. Interestingly, the structure-activity relationship revealed that the stereochemistry of the identified PPARα/γ dual agonists significantly affects their agonistic activities in PPARα than in PPARγ.

Design, synthesis, and evaluation of 2-alkoxydihydrocinnamates as PPAR agonists

A series of 2-alkoxydihydrocinnamates were synthesized as PPARγ and PPARα dual agonists. In vitro studies in cell model showed that these compounds were efficacious. Compound 1g was found to be a potent PPARα/γ dual agonist and will be further evaluated for the treatment of type II diabetes.